Volume Growth Subdued
Patient and test volume growth was only 4% versus industry ~10%, attributed to BMC contract exit and project suspensions. Management expects improvement but provided no specific recovery timeline.
KRSNAA / Q1-FY26 / risks
Keep the risk register visible.
Krsnaa Diagnostics · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Karnataka Revenue Disruption
Karnataka revenue declined due to procedural changes by state government. Management characterized impact as 'not significant' but did not quantify the revenue reduction, suggesting potential opacity.
Rajasthan Implementation Execution Risk
Deploying 42 mother labs, 135 satellite labs, and 1,335 collection centers over 6-9 months represents aggressive timeline. Prior PPP projects have seen implementation delays; management acknowledged history of similar challenges.
Revenue Share Cost Inflation
Rajasthan contract involves business partner revenue share, which management expects to increase. While confirming EBITDA margins will remain at current levels (~27%), the variable cost structure creates execution risk on margin sustainability.